Study | Study type and f/u | CNV cause | Patients | Total eyes | Treatment groups | ||
---|---|---|---|---|---|---|---|
Pathological myopia studies | |||||||
Iacono et al23 | Randomised, double-blind clinical trial, 18-month f/u | Myopia | Mean age: IVR 65 years, IVB 61 years % female: 76% Baseline VA: Mean letters: IVR 70±15, IVB 70±13 Ethnicity: NR (Italy) | 48 | IVR (mean number of injections 2.56, eyes=23) | IVB (mean number of injections 4.72, eyes=25) | |
Liu et al19 | Randomised controlled trial, 12-month f/u | Pathological myopia | Mean age: Control group 45.1 years, treatment group 43.5 years % female: control group 71%; treatment group 65% Baseline VA:* 66±16 letters(IVB+fufang xueshuantong) and 66±19 letters (fufang xueshuantong) Ethnicity: Chinese | 42 | FXT only (oral capsule 1.5 g TDS, eyes=20) | IVB+FXT (mean number of injections 3.86+1.5 g oral capsule TDS, eyes=22) | |
Gharbiya et al24 | Randomised controlled trial 6-month f/u | Pathological myopia | Mean age: IVR 60.63 years, IVB 59.06 years % female: 69% Baseline VA: ETDRS letters, IVR 26.44±12.58, IVB 29.50±12.98. Ethnicity: NR (Italy) | 32 | IVR 0.5 mg (mean number of injections 2.81, eyes=16) | IVB 1.25 mg (mean number of injections 2.44, eyes=16) | |
Wolf et al13 | Randomised controlled trial, double blind, 12-month f/u | Pathological myopia | Mean age: DA 56.1 years, STAB 54.0 years, PDT 57.4 years % female: DA 75%, STAB 77.4%, PDT 72.7% Baseline VA: ETDRS letters, mean: DA=55.8 (12.6), STAB=55.4 (13.4), PDT=54.7 (13.8) Ethnicity: (International) Caucasian 58%, Asian 41%, Other 1% | 277 | IVR 0.5 mg (retreatment based on disease activity (DA) criteria, mean number of injections NR eyes=116) | IVR 0.5 mg (retreatment based on stabilisation criteria (STAB), mean number of injections NR, eyes=106) | PDT (mean number of treatments NR, eyes=55) |
Hayashi et al25 | Prospective comparative study, 12 monnth f/u | Pathological myopia | Mean age: PDT 53 years, IVB 56.5 years % female: 73% Baseline VA: mean letters: PDT 70±21.5, IVB 66±14.5 Ethnicity: Japanese | 159 | Controls (eyes=74) | PDT (mean number of treatments 1.43, eyes=44) | IVB 1.25 mg (mean number of injections 1.6, eyes=43) |
Yoon et al26 | Retrospective comparative, 12-month f/u | Myopic CNV | Mean age: 44.9 years % female: 73% Baseline VA: Mean letters: PDT 73±18.5, Anti-VEGF 71±23, Combination 68±18.5 Ethnicity: NR (South Korea) | 142 | PDT (mean number of treatments 2.1, eyes=51) | Anti-VEGF—IVB 1.25 mg/IVR 0.05 mg (mean number of injections 2.2, eyes=63) | Combination—IVB 1.25 mg/IVR 0.05 mg+PDT (mean number of treatments, injections=1.9, PDT=1.9, eyes=28) |
El Matri et al20 | Retrospective comparative study, 12-month f/u | Pathological myopia | Mean age: PDT 53 years, IVB 55.8 years % female: 61% Baseline VA: mean letters: 56±22.5 (PDT), 55±42.5 (IVB) Ethnicity: North African (Tunisia) | 80 | PDT (mean number of treatments 1.55, eyes=40) | IVB 1.25 mg (mean number of injections 1.8, eyes=40) | |
El Matri et al27 | Retrospective comparative study, 24- month f/u | High myopia | Mean age: PDT 57 years, IVB 56 years % female: 65% Baseline VA: mean letters; PDT 56±38.5, IVB 55±17.5 Ethnicity: NR (France) | 60 | PDT (mean number of treatments 2.4, eyes=30) | IVB 1.25 mg (mean number of treatments 3.8, eyes=30) | |
Dethorey et al21 | Retrospective comparative study, median f/u; PDT group 53 months, IVR group 13.5 months | High myopia | Mean age: PDT 47 years, IVR 58 years % female: 83% Baseline VA: Snellen 20/80 (PDT), 20/160 (IVR) Ethnicity: NR (France) | 45 | PDT (mean number of treatments 2.5, eyes=27) | IVR 0.5 mg (mean number of treatments 3, eyes=18) | |
Yoon et al28 | Retrospective comparative study, 12-month f/u | Myopia | Mean age: 48.9 years % female: 82.5% Baseline VA: 75±13.5 letters Ethnicity: NR (S Korea) | 40 | IVR (mean number of injections 3.1, eyes=14) | IVB (mean number of injections 2.2, eyes=26) | |
Lai et al29 | Retrospective comparative study, 24 montths f/u | Pathological myopia | Mean age: 57.3 years % female: 62% Baseline VA: Mean letters: IVB 66±19.5, IVR 48±21.5 Ethnicity: Chinese | 37 | IVB 1.25 mg (mean number of injections 3.8, eyes=22) | IVR 0.5 mg (mean number of injections 3.8, eyes=15) | |
Ikuno et al30 | Retrospective comparative study, 24-month f/u | High myopia | Mean age: 67 years % female: 100% Baseline VA: mean letters: PDT 63±10, IVB 66±14.5, Ethnicity: Japanese | 31 | PDT (mean number of treatments 2.3, eyes=20) | IVB 1 mg (mean number of injections 2.9, eyes=11) | |
Baba et al31 | Retrospective comparative study, 24 months f/u | Myopic CNV | Mean age: 62.4 years % female: NR Baseline VA: mean letters 62±12.5 (IVB), 68±12.5 (PDT) Ethnicity: Japanese | 24 | PDT (mean number of treatments 1.3, eyes=12) | IVB 1.25 mg (mean number of injections 1.6 eyes=12) | |
Non-pathological myopia studies | |||||||
Kang and Koh 32 | Retrospective comparative study, 24-month f/u | Idiopathic | Mean age: 35.12 years % female: 60% Baseline VA: mean letters: PDT 72±19, anti-VEGF 77±29.5 Ethnicity: NR (S. Korea) | 29 | PDT (mean number of treatments 1.33, eyes=14) | Anti-VEGF (IVR 0.05mg=2 eyes, IVB 1.25 mg=13 eyes, mean number of injections 3.71, total eyes=15) | |
Parodi et al33 | Randomised controlled trial, 12 month f/u | Multifocal choroiditis | Mean age: 39 years % female: 66% Baseline VA: Mean letters; PDT 78±10, IVB 76±10 Ethnicity: NR (Italy) | 27 | PDT (mean number of treatments NR, eyes=13) | IVB (Mean number of injections NR, ‘loading phase of 3 monthly injections+further re-treatments’, eyes=14) | |
Cornish et al34 | Retrospective comparative study, average f/u 14.9 months | Punctate inner choroidopathy | Mean age: 34.4 years % female: 88% Baseline VA: 82±15.5 mean letters Ethnicity:NR (Scotland) | 18 | IVB 1.25 mg (6 patients, mean number of injections 2.34) | IVR 0.5 mg (3 patients, mean 2.34 injections) |
*Additional information taken from unpublished thesis, accessed at: http://www.docin.com/p-160870110.html.
CNV, choroidal neovascularisation; f/u, follow-up; FXT, fufang xueshuantong; IVB, intravitreal bevacizumab; IVR, intravitreal ranibizumab; NR, not reported; PDT, verteporfin photodynamic therapy, standard protocol as per verteporfin in photodynamic therapy study; TDS, three times daily; VA, visual acuity; VEGF, vascular endothelial growth factor.